Maitreyee Panda1, Akash Agarwal2, Trashita Hassanandani3. 1. Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, Orissa. Correspondence to: Dr Maitreyee Panda, Department of Dermatology, IMS and SUM Hospital, K-8 Kalinga Nagar, Bhubaneshwar, Odisha. pandamaitreyee@gmail.com. 2. Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, Orissa. 3. Department of Dermatology, Amaltas Institute of Medical Sciences, Dewas, Madhya Pradesh.
Abstract
CONTEXT: The clinical picture of pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection differs from adults as do the cutaneous manifestations. In this review, we summarize the varied morphological manifestations of SARS-CoV-2 infection in the pediatric population. EVIDENCE ACQUISITION: A comprehensive literature search was conducted (23 September, 2021) across multiple databases (PubMed, EMBASE, MEDLINE and Cochrane) with the relevant keywords. An additional filter of age group between 0-18 years was kept in each of the searches. RESULTS: Chilblains constitute the most common cutaneous manifestation of pediatric coronavirus disease (covid-19). Other commonly reported manifestations include maculopapular rash, urticaria, erythema multiforme, and papulovesicular eruptions. Majority of children with these manifestations are asymptomatic, highlighting the need to clinically suspect and appropriately manage such patients. A subset of pediatric patients develop severe multisystem involvement termed as multi-system inflammatory syndrome in children (MIS-C) that has varied mucocutaneous manifestations. CONCLUSION: A wide variety of dermatological manifestation of SARS-CoV-2 infection is reported, and both the pediatrician and dermatologist need to be aware of the same to suspect and diagnose COVID-19 infection in children.
CONTEXT: The clinical picture of pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection differs from adults as do the cutaneous manifestations. In this review, we summarize the varied morphological manifestations of SARS-CoV-2 infection in the pediatric population. EVIDENCE ACQUISITION: A comprehensive literature search was conducted (23 September, 2021) across multiple databases (PubMed, EMBASE, MEDLINE and Cochrane) with the relevant keywords. An additional filter of age group between 0-18 years was kept in each of the searches. RESULTS: Chilblains constitute the most common cutaneous manifestation of pediatric coronavirus disease (covid-19). Other commonly reported manifestations include maculopapular rash, urticaria, erythema multiforme, and papulovesicular eruptions. Majority of children with these manifestations are asymptomatic, highlighting the need to clinically suspect and appropriately manage such patients. A subset of pediatric patients develop severe multisystem involvement termed as multi-system inflammatory syndrome in children (MIS-C) that has varied mucocutaneous manifestations. CONCLUSION: A wide variety of dermatological manifestation of SARS-CoV-2 infection is reported, and both the pediatrician and dermatologist need to be aware of the same to suspect and diagnose COVID-19 infection in children.
Authors: Désirée Larenas-Linnemann; Jorge Luna-Pech; Elsy M Navarrete-Rodríguez; Noel Rodríguez-Pérez; Alfredo Arias-Cruz; María Virginia Blandón-Vijil; Blanca E Del Rio-Navarro; Alan Estrada-Cardona; Ernesto Onuma-Takane; Cesar Fireth Pozo-Beltrán; Adriana María Valencia-Herrera; Francisco Ignacio Ortiz-Aldana; Mirna Eréndira Toledo-Bahena Journal: Curr Allergy Asthma Rep Date: 2021-02-25 Impact factor: 4.806
Authors: L Navarro; D Andina; L Noguera-Morel; A Hernández-Martín; I Colmenero; A Torrelo Journal: J Eur Acad Dermatol Venereol Date: 2020-07-22 Impact factor: 9.228
Authors: Elizabeth Whittaker; Alasdair Bamford; Julia Kenny; Myrsini Kaforou; Christine E Jones; Priyen Shah; Padmanabhan Ramnarayan; Alain Fraisse; Owen Miller; Patrick Davies; Filip Kucera; Joe Brierley; Marilyn McDougall; Michael Carter; Adriana Tremoulet; Chisato Shimizu; Jethro Herberg; Jane C Burns; Hermione Lyall; Michael Levin Journal: JAMA Date: 2020-07-21 Impact factor: 157.335